Nidal Boulos
St. Jude Children's Research Hospital
20 Papers
123 Citations
Nidal Boulos is an academic researcher from St. Jude Children's Research Hospital. The author has contributed to research in topics: Dasatinib & Ependymoma. The author has an hindex of 11, co-authored 19 publications. Previous affiliations of Nidal Boulos include University of Cambridge.
Chat about Author
Papers
Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype.
Timothy N. Phoenix,Deanna M. Patmore,Scott Boop,Nidal Boulos,Megan O. Jacus,Yogesh T. Patel,Martine F. Roussel,David Finkelstein,Liliana Goumnerova,Sébastien Perreault,Elizabeth Wadhwa,Yoon Jae Cho,Clinton F. Stewart,Richard J. Gilbertson +13 more
TL;DR: It is shown that paracrine signals driven by mutant β-catenin in WNT-medulloblastoma induce an aberrant fenestrated vasculature that permits the accumulation of high levels of intra-tumoral chemotherapy and a robust therapeutic response, suggesting an approach to enhance the chemoresponsiveness of other brain tumors.
284
An integrated in vitro and in vivo high throughput screen identifies treatment leads for ependymoma
Jennifer M. Atkinson,Anang A. Shelat,Angel M. Carcaboso,Tanya A. Kranenburg,Leggy A. Arnold,Nidal Boulos,Karen Wright,Robert A. Johnson,Helen Poppleton,Kumarasamypet M. Mohankumar,Clementine Feau,Timothy N. Phoenix,Paul Gibson,Liqin Zhu,Yiai Tong,Christopher J. Eden,David W. Ellison,Waldemar Priebe,Dimpy Koul,W. K. Alfred Yung,Amar Gajjar,Clinton F. Stewart,R. Kiplin Guy,Richard J. Gilbertson +23 more
TL;DR: This comprehensive approach advances understanding of the biology and treatment of ependymoma including the discovery of several treatment leads for immediate clinical translation.
109
Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome–positive acute lymphoblastic leukemia
Nidal Boulos,Heather L. Mulder,Christopher R. Calabrese,Jeffrey B. Morrison,Jerold E. Rehg,Mary V. Relling,Charles J. Sherr,Richard Williams +7 more
TL;DR: Although non-tumor-cell-autonomous mechanisms can prevent full eradication of dasatinib-refractory ALL in this clinically relevant model, the emergence of resistance to BCR-ABL kinase inhibitors can be effectively circumvented by the addition of "conventional" chemotherapeutic agents with alternate antileukemic mechanisms of action.
81
Whole Body Physiologically-Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral Administration
Fan Zhang,Michael Tagen,Stacy L. Throm,Jeremy P. Mallari,Laura Miller,R. Kiplin Guy,Michael A. Dyer,Richard T. Williams,Martine F. Roussel,Katie Nemeth,Fangyi Zhu,Jiakun Zhang,Min Lu,John C. Panetta,Nidal Boulos,Clinton F. Stewart +15 more
TL;DR: The final PBPK model successfully described the plasma and tissue disposition of nutlin-3a and suggested high bioavailability, rapid attainment of steady state, and little accumulation when administered once or twice daily at dosages up to 400 mg/kg.
Orthotopic models of pediatric brain tumors in zebrafish
Christopher J. Eden,Bensheng Ju,Mohankumar Murugesan,Timothy N. Phoenix,Birgit Nimmervoll,Yiai Tong,David W. Ellison,David Finkelstein,Karen Wright,Nidal Boulos,Jason Dapper,Radhika Thiruvenkatam,Charles A. Lessman,Michael R. Taylor,Richard J. Gilbertson +14 more
TL;DR: It is demonstrated, for the first time, that mouse brain tumors can grow orthotopically in fish and serve as a platform to study drug efficacy as well as triage drug-leads from HTS for formal efficacy testing in mice.